Center for Drug Discovery, College of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Eur J Med Chem. 2011 May;46(5):1841-8. doi: 10.1016/j.ejmech.2011.02.046. Epub 2011 Feb 23.
Tetrabenazine (TBZ) ((±)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (±)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (Ki=4.47 nM) was 8000-fold more potent than (-)-1 (Ki=36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: Ki=3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders.
四苯嗪(TBZ)((±)-1)和二氢四苯嗪(DHTBZ)是 VMAT2 的强效抑制剂。本文描述了(±)-1 的实用化学拆分和所有八种 DHTBZ 立体异构体的立体选择性合成。VMAT2 结合测定的结果表明,(+)-1(Ki=4.47 nM)的活性比(-)-1(Ki=36,400 nM)高 8000 倍。在所有八种 DHTBZ 立体异构体中,(2R,3R,11bR)-DHTBZ((+)-2:Ki=3.96 nM)对 VMAT2 具有最大的亲和力。(3R,11bR)-构型似乎对 VMAT2 结合起关键作用。总之,(+)-1、(+)-2 及其衍生物值得进一步研究,以便开发更有效和更安全的药物,用于治疗亨廷顿病和其他运动障碍相关的舞蹈症。